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Abstract
Background—The Metabolic syndrome (MetS) and/or its individual components have been
linked to the development of cancer. Recent studies have suggested a similar link to
hepatocellular carcinoma (HCC). The aim of this study was to evaluate the direction and
magnitude of the association between the MetS and HCC.
Methods—Two reviewers independently conducted a systemic search to identify available
evidence from databases from January 1980 to June 2012. Search terms included ‘Metabolic
syndrome’, ‘insulin resistance syndrome’, ‘metabolic abnormalities’ combined with
‘hepatocellular carcinoma’ and ‘liver cancer’. No language restriction was applied to the search.
Only studies reporting an effect measure for the association between MetS and HCC were eligible
for inclusion. Publication bias was assessed using the Begg and Egger’s tests, with a visual
inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis
version 2 software.
Results—Four studies (3 cohort and 1 case-control) with a total of 829,651 participants were
included in the analysis. The age range of participants was between 30 and 84 years. The
combined analysis showed an overall 81% increase risk of HCC in cases with MetS (RR: 1.81,
95% CI: 1.37–2.41). After excluding the single case-control study from analysis, the overall risk
ratio remained statistically significant (RR: 1.49, 95% CI: 1.27–1.74). Funnel plot inspection,
Begg and Egger’s tests showed no evidence of publication bias for combined analysis.
Conclusions—Though studies are scarce, currently available epidemiologic data is suggestive
of significantly higher risk of hepatocellular carcinoma among patients with metabolic syndrome.
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BACKGROUND
Hepatocellular carcinoma (HCC) accounts for more than half a million new cases
worldwide, including around 20,000 new cases in the United States. Incidence of HCC in
the United States has tripled over the past decades, notably due to high prevalence of
hepatitis C infection. Although viral hepatitis and excessive alcohol use have been identified
as major risk factors for HCC, roughly 5% to 30% of HCC cases still lack identifiable
causes 1, 2.
Recent studies have shown that nonalcoholic fatty liver disease, the hepatic manifestation of
metabolic syndrome, is one of the risk factors for HCC. Metabolic syndrome (MetS) is an
assemblage of metabolic abnormalities including high body mass index or truncal obesity,
diabetes, insulin resistance, dyslipidemia, and elevated blood pressure 3. It is well known
that subjects with MetS are at significant risk of cardiovascular diseases 4. However, recent
studies have shown that MetS might have other adverse ramification, notably the
development of various types of cancers. The hallmark of this syndrome, hyperinsulinemia,
can induce cell proliferation through the interference with several signaling cascades and
disruption of the apoptotic pathway. Moreover, derangement in the adipokines such as
adiponectin; which is commonly observed in subjects with MetS, might also increase the
propensity of carcinogenesis 5. To support this assumption, several reports have
demonstrated the increasing risk of several cancers in subjects with MetS 6–8.
There are some studies linking obesity and diabetes with HCC suggesting that MetS might
play a role in the carcinogenesis 9, 10. The outcome from a few epidemiological studies
estimates that the risk of HCC is in fact increased by 1.5–2.0 folds in those with MetS 11, 12.
The accurate estimate on the magnitude of MetS and HCC is of importance given the rise in
the epidemic of obesity and MetS in the US population. Even a small increase in risk of
HCC from MetS can, therefore, account for significant increase in number of HCC cases
which may lead to profound economic impact 13.
In this study, we have conducted the systematic review and meta-analysis to evaluate all the
available evidence to determine the association between MetS and HCC.
METHODS
Search Strategy
We performed a literature search using PubMed, EMBASE and Cochrane database from
database inception to June 30, 2011 without language restriction using the following search
terms: metabolic syndrome, insulin resistance, metabolic abnormalities, primary liver
cancer, hepatoma and hepatocellular carcinoma. In addition, we carefully reviewed the
reference lists from all the articles to further identify relevant studies. The process of
systematic review was conducted in adherence to standards of quality for reporting meta-
analyses.
Eligibility criteria
Studies were included in the meta-analysis if they fulfilled the following criteria: (i) the
studies are either case-control or cohort design; (ii) the study subjects were ≥ 18 years old;
and (iii) they reported relative risk (RR) estimate for HCC in those with MetS. We included
Jinjuvadia et al. Page 2
J Clin Gastroenterol. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
all the publications with the use of various definitions of MetS (such as Third Report of the
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) 14, World Health Organization 15, International Diabetes
Federation 16, and the American Heart Association 17. In the circumstance when the reports
did not clearly delineate the definition of MetS, the RR estimate of HCC in individuals with
more than or equal to three metabolic abnormalities, based on Adult Treatment Panel III,
was considered in the analysis. If the same studied population were used by multiple studies
or if data were duplicated, only the estimates from the most recently published reports were
considered in the final analysis.
Data extraction
The following data were extracted from each study: publication data [first author’s last name
and first name initials, year of publication and country where the study was performed,
sample size, and participants’ demographic data], type of study design, number of cases and
controls (for case-control studies), number of exposed and unexposed (for cohort studies),
definitions of metabolic syndrome, risk estimates with their corresponding confidence
intervals (CIs), and all the covariates (if any) being used in the multivariate analyses and
modeling. We carefully reviewed the potential confounders, notably the use of alcohol; that
might be associated with the risk of HCC in the studied population. Odds ratios (ORs) from
case-control studies were considered as estimate of relative risk 18. Two independent
reviewers (RJ and SP) reviewed the studies and any discrepancies regarding inclusion/
exclusion or risk estimates were resolved through the discussion by the review team. The
agreement between reviewers for inclusion/exclusion of specific studies was assessed using
Cohen’s kappa coefficient 19.
Assessment of methodological quality
The Newcastle-Ottawa Scale was used for assessment of methodological quality of all the
publications that were included in the final analysis. The scales allocate stars, maximum of
nine, for quality of selection, comparability, exposure and outcome of study participants 20.
Statistical analysis
Summaries of relative risk (RR) estimates were evaluated using both fixed- and random-
effects methods. Initial analysis was performed to look for association between MetS and
HCC. The heterogeneity of all the publications was evaluated with Cochran’s Q-test and I2-
statistic 21. Publication bias was assessed by (i) construction and visual inspection of funnel
plot and (ii) employing the Egger’s22 and Begg and Mazumdar tests 23. Duval and
Tweedie’s trim and fill method was utilized to obtain RR after adjustments in the presence
of publication bias. The p value of < 0.05 indicated statistical significance. All analyses were
performed using Comprehensive Meta-analysis Version 2 (Biostat, Englewood, New
Jersey).
RESULTS
Literature Search and Study Characteristics
The schematic diagram of the detailed steps of our literature search is shown in Figure 1.
Briefly, we identified 1,500 studies from different databases, either in full publications or
abstract forms, using the methodology and the search terms described above [760 studies
from Pubmed, 120 studies from Cochrane database, 2 from EMBASE, and 600 abstracts
from the proceedings of the national meetings such as Digestive Disease Week and
American College of Gastroenterology]. After title appraisal, 141 publications were
considered to be potentially relevant. Of these, we excluded 55 review articles, 20 animal
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studies, 19 letters, 15 case reports, 5 pathological reports and 24 studies which did not
provide RR estimate. Three studies were considered for full article assessment and during
this process one additional relevant report was identified during the reference list review. A
total of 4 studies (3 cohort and one case-control studies) from the United States, Europe, and
Japan were included in the final analyses 11, 12, 24, 25. The observed Cohen’s kappa for the
agreement between reviewers was 0.75 26.
Association of metabolic syndrome and Hepatocellular carcinoma
Due to evidence of heterogeneity of the 4 studies (Q= 23.95, p value for heterogeneity =
0.001, I2=79.1%), we employed random-effect model to calculate the pooled RR. The
definitions of MetS that were used in these studies are outlined in Table 1. Among the 3
cohort studies, there were 630,049 participants, of which 4,055 had HCC. One case-control
study was published in 2011 using the SEER Medicare database comprising a total of 3,649
cases and 195,953 controls. The age of participants ranged from 30 to 84 years old. The
pooled RR (among 829,651 participants from 4 studies) for HCC among subjects with MetS
was 1.81 (95% CI 1.37–2.41) (Figure 2). The association remained significant when we only
considered 3 cohort studies in the analysis (RR: 1.49, 95% CI 1.27–1.74).
Publication quality and bias
The Newcastle-Ottawa Scale (range, 1–9 stars) to assess the publication quality revealed that
the average 7.7 stars for the three cohort studies and 6 for the one case-control study (Table
1). Visual inspection of funnel plot (Figures 2) and further evaluation with Egger’s and Begg
and Mazumdar tests for combined analysis of all 4 studies did not suggest evidence of
publication bias. (Begg and Mazumdar test: p = 0.85; Egger’s test: p = 0.57).
DISCUSSION
In this comprehensive review and meta-analysis, we found that metabolic syndrome
significantly increased the risk of HCC.
Besides from cardiovascular risks, MetS is being recognized as the risk factors for several
malignancies such as endometrial, colon, and prostate cancers 6–8. Our meta-analysis
including a large number of participants attests the results of previous studies on the link
between MetS and cancers suggesting the association between the presence of metabolic
abnormalities and the risk of HCC.
Despite our findings, it is still debatable on whether the increase in risk is in fact from the
specific components of metabolic derangement as opposed to the abnormalities in aggregate.
Many reports found that the high glucose level is associated with HCC 27, 28. This finding is
in fact supported by the recent meta-analysis showing the increasing in the relative risk of
HCC by 2.3-fold in those with diabetes 10. On the other hand, the association between the
level of cholesterol and HCC is conflicting. The study from Japan finds the positive
association between low levels of cholesterol and HCC 24; while the study from Italy reports
the contrary 11.
The pathogenesis of HCC in patients with metabolic syndrome is complex and multi
factorial. One plausible explanation is that it might be related to the presence of non-
alcoholic steatohepatitis and cirrhosis, a known risk factor for HCC 2. Whether patients with
MetS may develop HCC in the absence of cirrhosis is not well-defined. However, there are
some anecdotal reports supporting this circumstance and identifying MetS as an independent
predictor of HCC development. Study by Paradis et al 29 reported distinct pathological
characteristics of HCC in patients with MetS as the only risk factor, as compared to patients
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with chronic liver disease who follow fibrosis-cirrhosis-HCC pathway. Even among the
MetS subgroup, HCC occurred mainly in the setting of non-fibrotic liver which supported
the hypothesis of specific molecular pathway of liver tumorigenesis in MetS individuals 29.
Several molecular mechanisms, such as oxidative stress and reactive oxygen species
production, have been postulated for the risk of tumorigenesis among these individuals.
Reactive oxygen species can induce cancer promoting mutations such as mutation of p53
tumor suppressor gene and cause DNA damage 5. Another potential mechanism involves the
high level of insulin growth factor-1 in these subjects. This growth factor has been shown to
increase cell turnover and inhibits apoptosis; which may place individual at higher risk for
cancer development 30. Lastly such association might be associated with dysregulation of
inflammatory cytokines, i.e., tumor necrotic factor-alpha and interleukin-6, among subjects
with MetS 31. These cytokines have direct effect on hepatocytes and have been linked to
HCC development in animal model32.
Our systematic review has limitations. First, there are multiple factors that were not taken
into consideration for the pooled RR analysis such as dietary habits, family history of HCC,
and other genetic risk factors due to the unavailability of these variables in the original
studies. Second, the information on the underlying viral hepatitis is not obtainable, except
for the study by Welzel et al 12. Hepatitis C infection is a well-defined risk factor for HCC
and is an independent predictor of metabolic syndrome. One report showed no or minimal
changes in risk after further adjustment for hepatitis C infection on the association between
obesity or diabetes and liver cancer 33. It is still plausible that, the hepatitis C infection, if
present, might confound the reported magnitude of association between MetS and HCC in
our analysis. Third, it is also possible that subjects with alcoholic liver disease might be
included in the meta-analysis. Among the 4 studies11–2, 24–5, only the studies by Osaki and
Inoue24–5 described the definition of alcohol use in their studies. Inoue et al24, stratified
subjects (n =27,724) into 4 groups based in the weekly alcohol intake (non-drinkers, < 150
grams per week, 150–<300 grams per week, and ≥ 300 grams per week). On the other hand,
Osaki et al25, classified subjects as heavy drinking when the amount of alcohol consumed ≥
60 grams per day. Despite the difference in definitions, alcohol drinking status had been
adjusted in the Cox proportional hazard models in both studies. In our analysis, the potential
association between the use of alcohol in the study cohort and the risk of HCC has been
accounted for as we used the adjusted hazard ratios (adjusted for status of alcohol use) from
those two studies 24–5; when we calculated the relative risk estimates.
In summary, this meta-analysis shows that higher rates of HCC in subjects with MetS.
Because the increasing incidence of MetS in the Unites States; such association cannot be
disregarded. Timely preventive interventions targeted at reducing metabolic risk factors can
perhaps reduce the risk of HCC.
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Figure 1.
Study selection
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Figure 2.
Forest plot: Association between metabolic syndrome and Hepatocellular carcinoma
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Figure 3.
Funnel plots for publication bias: A) all studies, B) only cohort studies
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